The risk of relapse after treatment for childhood acute lymphoblastic leukaemia has decreased in the past 3 decades but the likelihood of successful treatment of relapse has not improved, suggests a review of three Nordic Society of Pediatric Hematology and Oncology clinical trials.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.